Interferon-β for multiple sclerosis: Long-term benefits?

Annals of Neurology

Volumn 61, Issue 4, 2007, Pages 283-285

  Rudick, Richard A ^a   Cutter, Gary ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; PLACEBO;

CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; EDITORIAL; FOLLOW UP; HUMAN; INFLAMMATION; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM;

BIOLOGICAL RESPONSE MODIFIERS; DISABILITY EVALUATION; DRUG ADMINISTRATION ROUTES; HUMANS; INTERFERON-BETA; LONGITUDINAL STUDIES; MULTIPLE SCLEROSIS; SEVERITY OF ILLNESS INDEX;

EID: 34247605400     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.21119     Document Type: Editorial

References (18)

1. The IFN-b Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:656-661.
2. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-294.
3. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998;352:1498-1504.
4. PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001;56:1628-1636.
5. Schwid SR, Bever CT Jr. The cost of delaying treatment in multiple sclerosis: what is lost is not regained. Neurology 2001;56:1620.
6. Rudick RA, Cutter GR, Baier M, et al. Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients. Mult Scler 2005;11:626-634.
7. Trojano M, Pellegrini F, Fuiani A, et al. New natural history of interferon-β-treated relapsing multiple sclerosis. Ann Neurol 2007;61:300-306.
8. Blackstone EH. Comparing apples and oranges. J Thorac Cardiovasc Surg 2002;123:8-15.
9. Grzybowski M, Clements EA, Parsons L, et al. Mortality benefit of immediate revascularization of acute ST-segment elevation myocardial infarction in patients with contraindications to thrombolytic therapy: a propensity analysis. JAMA 2003;290:1891-1898.
10. Ioannidis JP, Galanos O, Katritsis D, et al. Early mortality and morbidity of bilateral versus single internal thoracic artery revascularization: propensity and risk modeling. J Am Coll Cardiol 2001;37:521-528.
11. Gum PA, Thamilarasan M, Watanabe J, et al. Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease: a propensity analysis. JAMA 2001;286:1187-1194.
12. Sundararajan V, Mitra N, Jacobson JS, et al. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med 2002;136:349-357.
13. Kern LM, Powe NR, Levine MA, et al. Association between screening for osteoporosis and the incidence of hip fracture. Ann Intern Med 2005;142:173-181.
14. Foster EM. Propensity score matching: an illustrative analysis of dose response. Med Care 2003;41:1183-1192.
15. Rubin DB. The design versus the analysis of observational studies for causal effects: parallels with the design of randomized trials. Stat Med 2007;26:20-36.
16. Rudick RA, Lee JC, Simon J, et al. Significance of T2 lesions in multiple sclerosis: a 13-year longitudinal study. Ann Neurol 2006;60:236-242.
17. Brex PA, Ciccarelli O, O'Riordan JI, et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002;346:158-164.
18. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-285.